联合治疗-话题@MedSci

#联合治疗#

277篇内容 | 4235人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1313701, encodeId=a82c1313e011b, content=<a href='/topic/show?id=d4cc80e128f' target=_blank style='color:#2F92EE;'>#联合治疗#</a>, objectTitle=Ann Rheum Dis：托珠单抗与TNFi单药或与常规DMARDs联合治疗类风湿性关节炎的疗效比较, objectType=article, longId=137675, objectId=d4a413e67570, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d4a413e67570, replyNumber=0, likeNumber=70, createdTime=2018-05-11, rootId=0, userName=zhaozuguo, userId=263b421, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d4a413e67570, moduleTitle=Ann Rheum Dis：托珠单抗与TNFi单药或与常规DMARDs联合治疗类风湿性关节炎的疗效比较, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d4a413e67570)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1313700, encodeId=11e81313e001e, content=<a href='/topic/show?id=d4cc80e128f' target=_blank style='color:#2F92EE;'>#联合治疗#</a>, objectTitle=【中法国际乳腺癌学术论坛】张频教授：晚期乳腺癌内分泌联合治疗的优选, objectType=article, longId=136546, objectId=9d0f136546e3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9d0f136546e3, replyNumber=0, likeNumber=49, createdTime=2018-04-27, rootId=0, userName=zhaozuguo, userId=263b421, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9d0f136546e3, moduleTitle=【中法国际乳腺癌学术论坛】张频教授：晚期乳腺癌内分泌联合治疗的优选, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9d0f136546e3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1313699, encodeId=84241313699de, content=<a href='/topic/show?id=d4cc80e128f' target=_blank style='color:#2F92EE;'>#联合治疗#</a>, objectTitle=上海第三届西中医联合治疗心律失常高峰论坛暨稳心荣耀30年学术研讨会顺利召开, objectType=article, longId=136433, objectId=b11013643335, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b11013643335, replyNumber=0, likeNumber=52, createdTime=2018-04-27, rootId=0, userName=zhaozuguo, userId=263b421, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b11013643335, moduleTitle=上海第三届西中医联合治疗心律失常高峰论坛暨稳心荣耀30年学术研讨会顺利召开, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b11013643335)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1313698, encodeId=8285131369868, content=<a href='/topic/show?id=d4cc80e128f' target=_blank style='color:#2F92EE;'>#联合治疗#</a>, objectTitle=PD-L1/ CTLA-4免疫联合治疗非小细胞肺癌未能获益, objectType=article, longId=136414, objectId=1d661364149a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1d661364149a, replyNumber=0, likeNumber=0, createdTime=2018-04-26, rootId=0, userName=zhaozuguo, userId=263b421, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1d661364149a, moduleTitle=PD-L1/ CTLA-4免疫联合治疗非小细胞肺癌未能获益, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1d661364149a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1313697, encodeId=4f28131369e9f, content=<a href='/topic/show?id=d4cc80e128f' target=_blank style='color:#2F92EE;'>#联合治疗#</a>, objectTitle=上海第三届西中医联合治疗心律失常高峰论坛暨稳心荣耀30年学术研讨会, objectType=article, longId=135880, objectId=958c135880e8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=958c135880e8, replyNumber=0, likeNumber=63, createdTime=2018-04-21, rootId=0, userName=zhaozuguo, userId=263b421, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=958c135880e8, moduleTitle=上海第三届西中医联合治疗心律失常高峰论坛暨稳心荣耀30年学术研讨会, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=958c135880e8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1313696, encodeId=3aee131369605, content=<a href='/topic/show?id=d4cc80e128f' target=_blank style='color:#2F92EE;'>#联合治疗#</a>, objectTitle=Ophthalmologica：玻璃体腔内注射曲安奈德与白内障手术联合治疗效果评估, objectType=article, longId=135576, objectId=ea2f1355e6fd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ea2f1355e6fd, replyNumber=0, likeNumber=67, createdTime=2018-04-18, rootId=0, userName=zhaozuguo, userId=263b421, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ea2f1355e6fd, moduleTitle=Ophthalmologica：玻璃体腔内注射曲安奈德与白内障手术联合治疗效果评估, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ea2f1355e6fd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1313695, encodeId=4ea913136950e, content=<a href='/topic/show?id=d4cc80e128f' target=_blank style='color:#2F92EE;'>#联合治疗#</a>, objectTitle=Neurology：大血管闭塞患者采用IVT和MT联合治疗与直接MT治疗的安全和疗效比较！, objectType=article, longId=132803, objectId=f70713280326, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f70713280326, replyNumber=0, likeNumber=66, createdTime=2018-03-20, rootId=0, userName=zhaozuguo, userId=263b421, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f70713280326, moduleTitle=Neurology：大血管闭塞患者采用IVT和MT联合治疗与直接MT治疗的安全和疗效比较！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f70713280326)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1313694, encodeId=99f613136949e, content=<a href='/topic/show?id=d4cc80e128f' target=_blank style='color:#2F92EE;'>#联合治疗#</a>, objectTitle=NEJM：非洲隐球菌性脑膜炎的抗真菌联合治疗, objectType=article, longId=132496, objectId=3ef01324961e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3ef01324961e, replyNumber=0, likeNumber=55, createdTime=2018-03-17, rootId=0, userName=zhaozuguo, userId=263b421, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3ef01324961e, moduleTitle=NEJM：非洲隐球菌性脑膜炎的抗真菌联合治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3ef01324961e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1313693, encodeId=34ef1313693ae, content=<a href='/topic/show?id=d4cc80e128f' target=_blank style='color:#2F92EE;'>#联合治疗#</a>, objectTitle=Pharmazie：马来酸伊索拉定和阿奇霉素联合治疗可预防牙周炎的进展, objectType=article, longId=132139, objectId=e23b13213918, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e23b13213918, replyNumber=0, likeNumber=59, createdTime=2018-03-13, rootId=0, userName=zhaozuguo, userId=263b421, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e23b13213918, moduleTitle=Pharmazie：马来酸伊索拉定和阿奇霉素联合治疗可预防牙周炎的进展, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e23b13213918)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1313692, encodeId=8e8f131369210, content=<a href='/topic/show?id=d4cc80e128f' target=_blank style='color:#2F92EE;'>#联合治疗#</a>, objectTitle=J Clin Periodontol：自体血小板浓缩物对骨内缺损GTR/移植物联合治疗的影响, objectType=article, longId=130584, objectId=3ee413058409, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3ee413058409, replyNumber=0, likeNumber=25, createdTime=2018-02-26, rootId=0, userName=zhaozuguo, userId=263b421, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3ee413058409, moduleTitle=J Clin Periodontol：自体血小板浓缩物对骨内缺损GTR/移植物联合治疗的影响, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3ee413058409)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1313691, encodeId=f09f131369167, content=<a href='/topic/show?id=d4cc80e128f' target=_blank style='color:#2F92EE;'>#联合治疗#</a>, objectTitle=靶向联合治疗会是救命稻草吗？（三）最终临床方案的确定, objectType=article, longId=130415, objectId=1c7913041511, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1c7913041511, replyNumber=0, likeNumber=66, createdTime=2018-02-25, rootId=0, userName=zhaozuguo, userId=263b421, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1c7913041511, moduleTitle=靶向联合治疗会是救命稻草吗？（三）最终临床方案的确定, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1c7913041511)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1313690, encodeId=a5ed131369039, content=<a href='/topic/show?id=d4cc80e128f' target=_blank style='color:#2F92EE;'>#联合治疗#</a>, objectTitle=靶向联合治疗会是救命稻草吗？（二）如何发现更佳组合, objectType=article, longId=130414, objectId=24e5130414b7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=24e5130414b7, replyNumber=0, likeNumber=80, createdTime=2018-02-25, rootId=0, userName=zhaozuguo, userId=263b421, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=24e5130414b7, moduleTitle=靶向联合治疗会是救命稻草吗？（二）如何发现更佳组合, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=24e5130414b7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1313689, encodeId=809c13136897c, content=<a href='/topic/show?id=d4cc80e128f' target=_blank style='color:#2F92EE;'>#联合治疗#</a>, objectTitle=抗癌之路心惊胆战，耐药几乎不可避免，靶向联合治疗会是救命稻草吗？（一）, objectType=article, longId=130413, objectId=857f13041356, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=857f13041356, replyNumber=0, likeNumber=83, createdTime=2018-02-25, rootId=0, userName=zhaozuguo, userId=263b421, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=857f13041356, moduleTitle=抗癌之路心惊胆战，耐药几乎不可避免，靶向联合治疗会是救命稻草吗？（一）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=857f13041356)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1313688, encodeId=ca0013136885e, content=<a href='/topic/show?id=d4cc80e128f' target=_blank style='color:#2F92EE;'>#联合治疗#</a>, objectTitle=JAMA Oncol：那些因素限制局限期SCLC不能接受放化联合治疗？, objectType=article, longId=129882, objectId=7d9f129882b8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7d9f129882b8, replyNumber=0, likeNumber=70, createdTime=2018-02-15, rootId=0, userName=zhaozuguo, userId=263b421, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7d9f129882b8, moduleTitle=JAMA Oncol：那些因素限制局限期SCLC不能接受放化联合治疗？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7d9f129882b8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1313687, encodeId=0d9b131368e67, content=<a href='/topic/show?id=d4cc80e128f' target=_blank style='color:#2F92EE;'>#联合治疗#</a>, objectTitle=Liver Int：接受DAA与利巴韦林联合治疗的HCV患者，利巴韦林剂量的调整并不影响治疗效果, objectType=article, longId=128706, objectId=c333128e0626, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c333128e0626, replyNumber=0, likeNumber=72, createdTime=2018-02-04, rootId=0, userName=zhaozuguo, userId=263b421, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c333128e0626, moduleTitle=Liver Int：接受DAA与利巴韦林联合治疗的HCV患者，利巴韦林剂量的调整并不影响治疗效果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c333128e0626)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1313686, encodeId=2780131368697, content=<a href='/topic/show?id=d4cc80e128f' target=_blank style='color:#2F92EE;'>#联合治疗#</a>, objectTitle=正畸-修复联合治疗上前牙间隙一例, objectType=article, longId=127838, objectId=73de12e838f3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=73de12e838f3, replyNumber=0, likeNumber=0, createdTime=2018-01-28, rootId=0, userName=zhaozuguo, userId=263b421, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=73de12e838f3, moduleTitle=正畸-修复联合治疗上前牙间隙一例, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=73de12e838f3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1313685, encodeId=e83d13136858d, content=<a href='/topic/show?id=d4cc80e128f' target=_blank style='color:#2F92EE;'>#联合治疗#</a>, objectTitle=Lancet oncol：曲妥单抗、帕妥珠单抗、帕博西尼和氟维司群联合治疗HER2阳性、ER阳性的乳腺癌患者的效果和安全性。, objectType=article, longId=126038, objectId=58561260389d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=58561260389d, replyNumber=0, likeNumber=86, createdTime=2018-01-11, rootId=0, userName=zhaozuguo, userId=263b421, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=58561260389d, moduleTitle=Lancet oncol：曲妥单抗、帕妥珠单抗、帕博西尼和氟维司群联合治疗HER2阳性、ER阳性的乳腺癌患者的效果和安全性。, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=58561260389d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1313684, encodeId=675b13136847a, content=<a href='/topic/show?id=d4cc80e128f' target=_blank style='color:#2F92EE;'>#联合治疗#</a>, objectTitle=辉瑞/默克公司的avelumab与Inlyta联合治疗取得突破性进展, objectType=article, longId=124448, objectId=629b1244488f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=629b1244488f, replyNumber=0, likeNumber=54, createdTime=2017-12-25, rootId=0, userName=zhaozuguo, userId=263b421, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=629b1244488f, moduleTitle=辉瑞/默克公司的avelumab与Inlyta联合治疗取得突破性进展, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=629b1244488f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1313683, encodeId=b40a1313683e9, content=<a href='/topic/show?id=d4cc80e128f' target=_blank style='color:#2F92EE;'>#联合治疗#</a>, objectTitle=Circulation：依折麦布与辛伐他汀联合治疗的心血管结局和安全性分析！, objectType=article, longId=124177, objectId=bb401241e7b6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bb401241e7b6, replyNumber=0, likeNumber=72, createdTime=2017-12-23, rootId=0, userName=zhaozuguo, userId=263b421, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bb401241e7b6, moduleTitle=Circulation：依折麦布与辛伐他汀联合治疗的心血管结局和安全性分析！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bb401241e7b6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1313682, encodeId=32291313682c9, content=<a href='/topic/show?id=d4cc80e128f' target=_blank style='color:#2F92EE;'>#联合治疗#</a>, objectTitle=EUR J CANCER：紫杉醇、西妥昔单抗和放疗的联合治疗能够控制汗孔癌, objectType=article, longId=124077, objectId=968d1240e711, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=968d1240e711, replyNumber=0, likeNumber=54, createdTime=2017-12-22, rootId=0, userName=zhaozuguo, userId=263b421, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=968d1240e711, moduleTitle=EUR J CANCER：紫杉醇、西妥昔单抗和放疗的联合治疗能够控制汗孔癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=968d1240e711)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

联合治疗

2020-05-29

zhaozuguo (审核中...)

前往app查看评论内容

#联合治疗#

Ann Rheum Dis：托珠单抗与TNFi单药或与常规DMARDs联合治疗类风湿性关节炎的疗效比较

2018-05-11

zhaozuguo (审核中...)

前往app查看评论内容

#联合治疗#

【中法国际乳腺癌学术论坛】张频教授：晚期乳腺癌内分泌联合治疗的优选

2018-04-27

zhaozuguo (审核中...)

前往app查看评论内容

#联合治疗#

上海第三届西中医联合治疗心律失常高峰论坛暨稳心荣耀30年学术研讨会顺利召开

2018-04-27

zhaozuguo (审核中...)

前往app查看评论内容

#联合治疗#

PD-L1/ CTLA-4免疫联合治疗非小细胞肺癌未能获益

2018-04-26

zhaozuguo (审核中...)

前往app查看评论内容

#联合治疗#

上海第三届西中医联合治疗心律失常高峰论坛暨稳心荣耀30年学术研讨会

2018-04-21

zhaozuguo (审核中...)

前往app查看评论内容

#联合治疗#

Ophthalmologica：玻璃体腔内注射曲安奈德与白内障手术联合治疗效果评估

2018-04-18

zhaozuguo (审核中...)

前往app查看评论内容

#联合治疗#

Neurology：大血管闭塞患者采用IVT和MT联合治疗与直接MT治疗的安全和疗效比较！

2018-03-20

zhaozuguo (审核中...)

前往app查看评论内容

#联合治疗#

NEJM：非洲隐球菌性脑膜炎的抗真菌联合治疗

2018-03-17

zhaozuguo (审核中...)

前往app查看评论内容

#联合治疗#

Pharmazie：马来酸伊索拉定和阿奇霉素联合治疗可预防牙周炎的进展

2018-03-13

zhaozuguo (审核中...)

前往app查看评论内容

#联合治疗#

J Clin Periodontol：自体血小板浓缩物对骨内缺损GTR/移植物联合治疗的影响

2018-02-26

zhaozuguo (审核中...)

前往app查看评论内容

#联合治疗#

靶向联合治疗会是救命稻草吗？（三）最终临床方案的确定

2018-02-25

zhaozuguo (审核中...)

前往app查看评论内容

#联合治疗#

靶向联合治疗会是救命稻草吗？（二）如何发现更佳组合

2018-02-25

zhaozuguo (审核中...)

前往app查看评论内容

#联合治疗#

抗癌之路心惊胆战，耐药几乎不可避免，靶向联合治疗会是救命稻草吗？（一）

2018-02-25

zhaozuguo (审核中...)

前往app查看评论内容

#联合治疗#

JAMA Oncol：那些因素限制局限期SCLC不能接受放化联合治疗？

2018-02-15

zhaozuguo (审核中...)

前往app查看评论内容

#联合治疗#

Liver Int：接受DAA与利巴韦林联合治疗的HCV患者，利巴韦林剂量的调整并不影响治疗效果

2018-02-04

zhaozuguo (审核中...)

前往app查看评论内容

#联合治疗#

正畸-修复联合治疗上前牙间隙一例

2018-01-28

zhaozuguo (审核中...)

前往app查看评论内容

#联合治疗#

Lancet oncol：曲妥单抗、帕妥珠单抗、帕博西尼和氟维司群联合治疗HER2阳性、ER阳性的乳腺癌患者的效果和安全性。

2018-01-11

zhaozuguo (审核中...)

前往app查看评论内容

#联合治疗#

辉瑞/默克公司的avelumab与Inlyta联合治疗取得突破性进展

2017-12-25

zhaozuguo (审核中...)

前往app查看评论内容

#联合治疗#

Circulation：依折麦布与辛伐他汀联合治疗的心血管结局和安全性分析！

2017-12-23

zhaozuguo (审核中...)

前往app查看评论内容

#联合治疗#

EUR J CANCER：紫杉醇、西妥昔单抗和放疗的联合治疗能够控制汗孔癌

2017-12-22

科室
- - 订阅+
  - 更多科室
工具
服务